Home / Late quarterly reports / Liminatus Pharma, Inc.
Filed 2025-05-15 路 Form NT 10-Q 路 Accession 0001104659-25-049500 micro
Price before filing: $325 (2025-05-14 close, split/dividend-adjusted)
Market cap at flag: $154.5M (2025-05-15) 路 Latest: $1.4M (2026-10-16)
| Window | LIMN | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | +86.3% | +2.6% | +83.7% | 2025-06-16 |
| 90 days | -32.3% | +10.1% | -42.4% | 2025-08-13 |
| 180 days | -82.0% | +16.9% | -98.9% | 2025-11-11 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
"We could not timely file our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, because the financial statements could not be completed in sufficient time to solicit and obtain the necessary review of the subject report and signatures thereto in a timely fashion prior to the due date of the report."
Quoted from the filing. Source
The company told the SEC it could not file its quarterly report on time (Form NT 10-Q) and then missed the 5-day extension too. Repeated late filings are a stronger warning.
Status: filed late (report filed 2025-06-02)
Why this score: filed late on 2025-06-02; also within 90 days: Auditor change, Going-concern doubt
Read the original filing on SEC.gov →
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Newsletter delivered by beehiiv. See our privacy policy.